Memorial Sloan Kettering Cancer Center

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Myeloma
Leukemia
Lymphoma
Hematologic Transplantation and Malignancies
Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic
Skin
Head and Neck
Brain
General Oncology
Palliative Care
MPN
COVID-19
Events

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

2019 ASH Review on Combinations or Sequences of Targeted Agents in CLL: Ibrutinib + Venetoclax for the 1st-Line Treatment - Should MRD Status at EOT Be Driving Treatment Decisions?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato

0 views

April 14, 2020

Comments 0

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Leukemia